-
Mashup Score: 48
This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical decision-making queries encountered in everyday practice, such as the optimal treatment strategy for PD-L1–high patients, predictive factors for response to immune checkpoint inhibitors (ICI) both in terms of patient and cancer characteristics, the potential benefits of dual checkpoint blockade, and the unresolved issue of safe discontinuation strategies for long-term responders. Around one in five patients falls into this latter category while the majority develop either primary or acquired resistance to ICI-based first-line therapy, necessitating effective subsequent lines of treatment. Docetaxel, with or without combination of antiangiogenic agents, serves as the backbone of treatment, although evidence in the post-ICI setting is limited. Given that an inflamed tumor microenvironment (TME) is crucia
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0F.T.C. Issues Ban on Worker Noncompete Clauses - 4 day(s) ago
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0F.T.C. Issues Ban on Worker Noncompete Clauses - 4 day(s) ago
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors - 25 day(s) ago
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic treatment options, improving patients’ outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43
Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab–platinum–pemetrexed (induction) in US community oncology settings. Methods: Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). Results: Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrol
Source: www.futuremedicine.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Click here to support the 2024 Orange HS Track Fundraiser - 2 month(s) ago
We are currently running a fundraiser to help raise money and to ensure we have a successful season. Your donation will help us buy equipment like resistance bands, towels, relay batons, and other misc items that we use for our sport, in addition to senior gifts and spring sports awards. We have the largest team on campus, and having team funds available to make these purchases is extraordinarily helpful. We are looking to our families, friends, and community to help us offset these costs. Please take 5 minutes and donate whatever you can — even the smallest donation makes a difference! Each participant has an individual goal of raising $500.00 for this fundraiser. Please help our student-athletes achieve their goals! Thank you, Coach Frutkin
Source: wefund4u.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 99Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report - 3 month(s) ago
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Update on Biomarkers in Renal Cell Carcinoma - 3 month(s) ago
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and durable responses. However, given the multiple ICI-containing, standard-of-care regimens approved for RCC, identifying biomarkers that predict therapeutic response and resistance is of critical importance. Although tumor-intrinsic features such as pathological characteristics, genomic alterations, and transcriptional signatures have been extensively investigated, they have yet to provide definitive, robust predictive biomarkers. Current research is exploring host factors through in-depth characterization of the immune system. Additionally, innovative technological approaches are being developed to overcome challenges presented by existing techniques, such as tumor heterogeneity. Promising avenues in biomarker discovery include the study of the microbiome, radiomics, and spatial transcriptomics
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49De-Escalation of Therapy for Prostate Cancer - 3 month(s) ago
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men with around 1.4 million new cases every year. In patients with localized disease, management options include active surveillance (AS), radical prostatectomy (RP; with or without pelvic lymph node dissection), or radiotherapy to the prostate (with or without pelvic irradiation) with or without hormonotherapy. In advanced disease, treatment options include systemic treatment(s) and/or treatment to primary tumour and/or metastasis-directed therapies (MDTs). Specifically, in advanced stage, the current trend is earlier intensification of treatment such as dual or triple combination systemic treatments or adding treatment to primary and MDT to systemic treatment. However, earlier treatment intensification comes with the cost of increased morbidity and mortality resulting from drug-/treatment-related side effects. The main goal is and should be to provide the best possible care and oncologic outcomes with minimum possi
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 79Immuno-Oncology Advances in Genitourinary Cancers - 3 month(s) ago
Immuno-oncology (IO) has made monumental gains in the past decade in the genitourinary space. In this review, we highlight advances with IO in renal cell carcinoma where it now has become standard-of-care frontline therapy in the metastatic setting but also discuss challenges with the initial approach. In urothelial carcinoma, we discuss the growing use of IO including exciting recent updates with IO-based regimens that may soon become the new standard of care. We further discuss difficulties with IO in prostate cancer, germ cell tumors, and penile squamous cell carcinoma. Finally, we highlight advances in IO approaches beyond checkpoint inhibition including the role of the gut microbiome and T-cell redirecting therapies.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations | American Society of Clinical Oncology Educational Book https://t.co/5jTCWpVatj #ASCO24 #LCSM @MartinReck2